Failure after radical prostatectomy

Urology

Volumn 61, Issue 1, 2003, Pages 30-36

  Neulander, Endre Z ^a,b   Soloway, Mark S ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; CAPROMAB PENDETIDE IN 111; FINASTERIDE; GONADORELIN AGONIST; INDIUM 111; PROSTATE SPECIFIC ANTIGEN;

BONE SCINTISCANNING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MECHANISM; FOLLOW UP; HEALTH STATUS; HORMONAL THERAPY; HUMAN; METASTASIS; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT DISEASE; REVIEW; SCORING SYSTEM; TREATMENT FAILURE;

BIOPSY, NEEDLE; HUMANS; MALE; MODELS, STATISTICAL; NEOPLASM STAGING; PREOPERATIVE CARE; PROBABILITY; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; SALVAGE THERAPY; SEMINAL VESICLES; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE;

EID: 0037253542     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01918-0     Document Type: Review

References (55)

1. Ornstein D.K., Colberg J.W., Virgo K.S., et al. Evaluation and management of men whose radical prostatectomies failed results of an international survey. Urology. 52:1998;1047-1054.
2. Pound C.R., Partin A.W., Epstein J.I., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy patterns of recurrence and cancer control. Urol Clin North Am. 24:1997;395-406.
3. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
4. Obek C., Sadek S., Lai S., et al. Positive surgical margins with radical retropubic prostatectomy anatomic site-specific pathologic analysis and impact on prognosis. Urology. 54:1999;682-688.
5. Catalona W.J., Smith D.S. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer intermediate-term results. J Urol. 160:1998;2428-2434.
6. Kupelian P.A., Katcher J., Levin H.S., et al. Stage T1-2 prostate cancer a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys. 37:1997;1043-1052.
7. Jhaveri F.M., Zippe C.D., Klein E.A., et al. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer 10-year results. Urology. 54:1999;884-890.
8. Lerner SE, Blute ML, Zincke H. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 14(2 suppl 2): 12-21, 1996.
9. Partin A.W., Pound C.R., Clemens J.Q., et al. Serum PSA after anatomic radical prostatectomy the Johns Hopkins experience after 10 years. Urol Clin North Am. 20:1993;713-725.
10. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer a multi-institutional update. [published erratum appears in JAMA 278: 118, 1997] JAMA. 277:1997;1445-1451.
11. Epstein J.I., Partin A.W., Sauvageot J., et al. Prediction of progression following radical prostatectomy a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 20:1996;286-292.
12. Stein A., deKernion J.B., Dorey F., et al. Adjuvant radiotherapy in patients post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles. Urology. 39:1992;59-62.
13. Wheeler T.M., Dillioglugil O., Kattan M.W., et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 29:1998;856-862.
14. Wieder J.A., Soloway M.S. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol. 160:1998;299-315.
15. Grossfeld G.D., Chang J.J., Broering J.M., et al. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment data from the CaPSURE database. J Urol. 163:2000;1171-1177. (quiz 1295).
16. Kattan M.W., Wheeler T.M., Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 17:1999;1499-1507.
17. Obek C., Neulander E., Sadek S., et al. Is there a role for digital rectal examination in the followup of patients after radical prostatectomy? J Urol. 162:((3 Pt 1):):1999;762-764.
18. Pound C.R., Christens-Barry O.W., Gurganus R.T., et al. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol. 162:1999;1337-1340.
19. Lightner D.J., Lange P.H., Reddy P.K., et al. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol. 144:1990;921-926.
20. Patel A., Dorey F., Franklin J., et al. Recurrence patterns after radical retropubic prostatectomy clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 158:1997;1441-1445.
21. Jhaveri F.M., Klein E.A. How to explore the patient with a rising PSA after radical prostatectomy defining local versus systemic failure. Semin Urol Oncol. 17:1999;130-134.
22. Fowler J.E. Jr, Brooks J., Pandey P., et al. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol. 153:(3 Pt 2):1995;1011-1014.
23. Saleem M.D., Sanders H., Abu El Naser M., et al. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology. 51:1998;283-286.
24. Shekarriz B., Upadhyay J., Wood D.P. Jr, et al. Vesicourethral anastomosis biopsy after radical prostatectomy predictive value of prostate-specific antigen and pathologic stage. Urology. 54:1999;1044-1048.
25. Koppie T.M., Grossfeld G.D., Nudell D.M., et al. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol. 166:2001;111-115.
26. Partin A.W., Pearson J.D., Landis P.K., et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 43:1994;649-659.
27. Seltzer M.A., Barbaric Z., Belldegrun A., et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 162:1999;1322-1328.
28. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol. 163:2000;1632-1642.
29. Kahn D., Williams R.D., Haseman M.K., et al. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 16:1998;284-289.
30. Leibovich B.C., Engen D.E., Patterson D.E., et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol. 163:2000;1178-1182.
31. Morris M.M., Dallow K.C., Zietman A.L., et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 38:1997;731-736.
32. Vicini F.A., Ziaja E.L., Kestin L.L., et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology. 54:1999;111-117.
33. Petrovich Z., Lieskovsky G., Langholz B., et al. Comparison of outcomes of radical prostatectomy with and without adjuvant pelvic irradiation in patients with pathologic stage C (T3N0) adenocarcinoma of the prostate. Am J Clin Oncol. 22:1999;323-331.
34. Valicenti R.K., Gomella L.G., Ismail M., et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer the importance of radiation dose. Urology. 52:1998;1034-1040.
35. Valicenti R.K., Gomella L.G., Ismail M., et al. Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma effect of early adjuvant radiation therapy on biochemical control. Cancer. 82:1998;1909-1914.
36. Grossfeld G.D., Tigrani V.S., Nudell D., et al. Management of a positive surgical margin after radical prostatectomy decision analysis. J Urol. 164:2000;93-100.
37. Valicenti R.K., Gomella L.G. Durable efficacy of adjuvant radiation therapy for prostate cancer will the benefit last? Semin Urol Oncol. 18:2000;115-120.
38. Rogers R., Grossfeld G.D., Roach M. III, et al. Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. J Urol. 160:1998;1748-1753.
39. Pisansky T.M., Kozelsky T.F., Myers R.P., et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 163:2000;845-850.
40. Tiguert R., Forman J.D., Hussain M., et al. Radiation therapy for a rising PSA level after radical prostatectomy. Semin Urol Oncol. 17:1999;141-147.
41. Nudell D.M., Grossfeld G.D., Weinberg V.K., et al. Radiotherapy after radical prostatectomy treatment outcomes and failure patterns. Urology. 54:1999;1049-1057.
42. Schild S.E., Buskirk S.J., Wong W.W., et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol. 156:1996;1725-1729.
43. Garg M.K., Tekyi-Mensah S., Bolton S., et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology. 51:1998;998-1002.
44. Cox J.D., Gallagher M.J., Hammond E.H., et al. Consensus statements on radiation therapy of prostate cancer guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol. 17:1999;1155.
45. Nelson W.G., Simons J.W. New approaches to adjuvant therapy for patients with adverse histopathologic findings following radical prostatectomy. Urol Clin North Am. 23:1996;685-696.
46. Mayer F.J., Crawford E.D. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy. Urol Clin North Am. 21:1994;707-715.
47. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 341:1999;1781-1788.
48. Bruchovsky N., Klotz L.H., Sadar M., et al. Intermittent androgen suppression for prostate cancer Canadian prospective trial and related observations. Mol Urol. 4:2000;191-200.
49. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Intermittent androgen suppression in the treatment of prostate cancer a preliminary report. Urology. 45:1995;839-845.
50. Zerbib M., Conquy S. Intermittent hormonal treatment in prostatic cancer. Prog Urol. 7:1997;1026-1027.
51. Bouchot O., Lenormand L., Karam G., et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol. 38:2000;543-549.
52. Bhayani S.B., Andriole G.L. Hormonal manipulation for rising PSA after radical prostatectomy. Semin Urol Oncol. 17:1999;148-153.
53. Iversen P., Tyrrell C.J., Kaisary A.V., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer 6.3 years of followup. J Urol. 164:2000;1579-1582.
54. Andriole G., Lieber M., Smith J., et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 45:1995;491-497.
55. Brufsky A., Fontaine-Rothe P., Berlane K., et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology. 49:1997;913-920.